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Introduction
Atypical ductal hyperplasia (ADH) is a benign pro-
liferative lesion, but due to a risk of coexisting can-
cer it is classified as B3 diagnostic category, covering 
lesions of uncertain malignant potential [1, 2]. It is 
characterized by proliferation of monomorphic, even-
ly distributed epithelial cells in the terminal duct-
al-lobular unit. Atypical ductal hyperplasia resembles 
low-grade ductal carcinoma in situ (DCIS), but it dif-
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A b s t r a c t
Introduction: Atypical ductal hyperplasia (ADH) is a benign lesion, which due to the risk of coexisting cancer is clas-
sified as a lesion of uncertain malignant potential. 
Aim: To identify clinical predictors of cancer underestimation in patients with ADH diagnosed after vacuum-assisted 
breast biopsy (VABB). 
Material and methods: Between 2001 and 2016, a total of 3804 vacuum-assisted core needle biopsies were per-
formed at the First Chair of General Surgery of the Jagiellonian University Medical College in Krakow, including 
2907 ultrasound (US)-guided biopsies and 897 digital stereotactic procedures. Seventy-six women were diag-
nosed with ADH and 72 of them underwent subsequent surgical excision. Demographic factors, medical history, 
family history, clinical symptoms, type and size of lesion determined in imaging scans, size of biopsy needle, and 
presence of coexisting lesions in VABB specimens were analysed as potential predictors of malignancy underes-
timation.
Results: Underestimation of breast carcinoma occurred in 21 (29.2%) patients. The upgrade rate was significantly 
higher only in patients with a  lesion visible both in mammography (MMG) and US examinations and combined 
BIRADS-5.
Conclusions: Vacuum-assisted core needle biopsy is a minimally invasive technique used in diagnosing ADH. As 
the risk of breast malignancy underestimation is relatively high, open surgical biopsy remains the recommended 
procedure, especially in patients with lesions detected both in mammography and US examination. As we could not 
identify the factors that preclude cancer underestimation, all the women diagnosed with ADH should be informed 
about the risk of cancer underestimation.
Key words: atypical ductal hyperplasia, breast cancer underestimation, vacuum-assisted core needle biopsy.
General surgery
Clinical predictors of malignancy in patients diagnosed with atypical ductal hyperplasia on vacuum-assisted core needle biopsy
185Videosurgery and Other Miniinvasive Techniques 2, June/2018
fers by an admixed population of non-monomorphic 
cells or by a size limit – involvement of less than two 
duct spaces or an area of less than 2 mm in diameter 
[3, 4].
The definition of atypical ductal hyperplasia is 
based on excisional breast biopsy specimens and 
due to the limited material obtained from stand-
ard core-needle biopsy (CNB), a definitive diagnosis 
in such cases is hardly possible [3]. The decision to 
perform surgical excision of the lesion diagnosed as 
ADH after CNB is justified by a  30–54% incidence 
of DCIS or invasive breast carcinoma in the material 
from the surgical specimens [2, 5–7]. Vacuum-assist-
ed core needle biopsy (vacuum-assisted breast biop-
sy – VABB) provides bigger samples, and therefore 
the underestimation of malignancy is distinctly low-
er, in the range 9–36% [8–11].
Factors increasing the risk of cancer underesti-
mation include breast symptoms, findings in mam-
mography other than microcalcifications alone, size 
of biopsy needle, number of biopsy samples, coex-
isting intraductal papilloma, diagnosis of marked 
atypia and experience level of the pathologist [6, 
12]. There is also a higher risk of underestimation in 
patients over 60 years of age, with family history of 
breast cancer, or in patients who had breast cancer 
before [9, 13].
Although there are no doubts regarding the rec-
ommendations for excisional biopsy, in the case of 
ADH diagnosed with CNB, such indications for VABB 
are inconsistent [8, 14–18].
As reported in the literature, the chances for un-
derestimation become distinctly lower when mul-
tiple samples are taken and the lesion removal on 
post-biopsy mammograms is complete [8, 14–16].
Aim
The aim of this study was to identify clinical pre-
dictors of cancer underestimation in patients with 
ADH diagnosed after VABB.
Material and methods
Between 2001 and 2016, in the Regional Out-
patient Clinic of Early Diagnosis and Treatment of 
Breast Diseases at the First Chair of General Sur-
gery of the Jagiellonian University Medical College in 
Krakow, a total of 3804 vacuum-assisted core nee-
dle biopsies were performed. They included 2907 
US-guided biopsies and 897 digital stereotactic 
procedures. Of these, 76 (1.99%) women were diag-
nosed with ADH. The rate of procedure-related com-
plications was about 1.5%, with haematoma being 
the most common adverse event.
In the whole study population, ADH was diag-
nosed in 1.6% of patients who underwent US-guid-
ed biopsy, and in 3.1% subjected to stereotactic bi-
opsy. The rate of ADH diagnosis in patients in whom 
only microcalcifications were diagnosed was 6.6% 
(28/421). In cases where the lesion was not visible 
in US, stereotactic digital mammography-guided 
biopsy was performed. Other patients underwent 
US-guided biopsies. 
Seventy-two patients from the group of 76 pa-
tients diagnosed with ADH underwent subsequent 
surgical excision and were followed up with mam-
mography/US examinations after six months and 
then annually independently of the final diagnosis. 
The follow-up ranged from 18 months to 15 years, 
the average being 6.7 years. Four women who were 
not subjected to open surgical biopsy were exclud-
ed from the analysis. Two of them refused the pro-
cedure and were followed up only, one was diag-
nosed with synchronous breast carcinoma, and the 
fourth one underwent further treatment in another 
centre.
All patients underwent breast ultrasound and 
mammography. Clinical data were obtained from 
their medical records and included patient’s age, 
menopausal status, family history of breast cancer, 
history of previous or presence of synchronous breast 
carcinoma, clinical symptoms (nipple discharge, 
pain, itching), type and size of lesion determined 
in mammography and/or in US, Breast Imaging and 
Reporting Data System (BIRADS) classification of 
mammographic and US findings, presence of micro-
calcifications, and size of biopsy needle. Presence of 
coexisting intraductal papilloma or fibroadenoma in 
VABB specimens was also recorded. 
Core biopsies were performed using 7 G (23 cas-
es – 31.9%), and 10 G or 11 G (49 patients – 68.1%) 
needles. The number of biopsy specimens ranged 
from 5 to 14, i.e. 7 on average. 
The specimens were fixed in 10% neutral buff-
ered formalin solution and sent for histopathological 
evaluation to the Chair of Pathomorphology of the 
Jagiellonian University Medical College. For the pur-
pose of this study, all biopsy specimens were verified 
by a second pathologist who was not aware of the 
post-excisional pathologic results.
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Twenty-eight (38.9%) of the studied 72 biopsies 
were stereotactic and 44 (61.1%) US-guided. The 
mean age of patients in the study group was 53.4 
±11.56 years and ranged from 28 to 79 years. The 
clinical characteristics of the study group are sum-
marized in Table I. 
Morphologically, there were 44 (61.1%) solid 
masses detected at US examination, while the mam-
mography revealed: 25 (35.8%) masses, 24 clusters 
or areas of microcalcifications (35.8%) and 3 archi-
tectural distortions (4.5%) (Table II).
Statistical analysis
For each analysed predictive factor, an odds ra-
tio (OR) was calculated with 95% confidence inter-
val (95% CI). For multifactorial analysis, a binary logit 
model of logistic regression was applied. The level of 
significance was set at p ≤ 0.05. Statistical calcula-
tions were performed using the Statistica 10 package.
Results
For the purpose of this study, all biopsy speci-
mens were assessed by a  second pathologist who 
was blinded to the final diagnosis to confirm the in-
itial finding of ADH. 
In 2 cases, the results of the second pathologic 
examination of the VABB specimens revealed mod-
erate suspicion of DCIS, but not invasive cancer. 
In the group of 72 women who underwent sur-
gical excision, the final pathologic report revealed 
non-malignant lesions in 51 (70.8%) and 21 (29.2%) 
malignant lesions.
The benign findings were ADH in 13 patients, 
usual ductal hyperplasia (UDH) in 20 patients, 12 in-
traductal papillomas, 5 fibroadenomas and 2 lobular 
carcinomas in situ (LCIS). In the group of malignant 
lesions, there were 11 invasive ductal carcinomas 
and 10 cases of DCIS. The mean age of women with 
malignant lesions was 56.8 ±13.02 years and ranged 
from 34 to 78 years. In the group of benign lesions 
the mean age of patients was 52 ±10.73 years and 
ranged from 28 to 75 years. The analysis of BIRADS 
score obtained from mammography and US showed 
that because some of the lesions were visible in 
one of the imaging methods only (16 not visible in 
MMG and 29 not visible in US), a substantial num-
ber of cases should not be included in the analysis. 
Therefore, the highest BIRADS score in either MMG 
or US was adopted as the combined BIRADS. In the 
group of invasive cancers, 6 patients were assessed 
as BIRADS 5 and in the DCIS group, 2 (Table III). Only 
1 patient with a benign lesion received BIRADS 5 in 
US. None of the patients with malignant lesion was 
assessed as BIRADS 1–3, but only 3 patients with 
a benign lesion were within these BIRADS limits. 
Multiple clinical data were analysed as potential 
predictors of malignancy underestimation (Table IV). 
Among these factors, the presence of clinical symp-
Table I. Clinical and morphological features of 
the study group
Clinical and morphological 






≤ 60 55 76.4




Family history of disease:
Yes 13 18.1
No 59 81.9
History of synchronous/undergone breast cancer:
Yes 4 5.6
No 68 94.4
Asymptomatic lesion 47 65.3
Symptomatic lesion 25 34.7
Lesion size (the largest size in USG/MMG) [mm]a:
< 10 37 51.4
10–20 20 27.8
> 20 12 16.7
Lesion visible only in USG 18 25
Lesion visible only in MMG 23 31.9
Lesion visible in both examina-
tions
31 43.1
Papilloma or fibroadenoma co-diagnosis:
Yes 18 25
No 54 75
USG – ultrasonography, MMG – mammography. aIn 3 patients the size of the 
lesion was not calculated.
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toms (OR = 2.9), the visibility of the lesion in both 
imaging methods (OR = 4.37), the visibility of the le-
sion in MMG (OR = 10.9), the size over 1 cm (OR = 
3.41) and the combined BIRADS-5 (OR = 15.62) were 
assessed as statistically significant predictive factors. 
Neither age nor menopausal status was a  predictor 
of malignancy underestimation. Patient’s history and 
family history had no impact on cancer underestima-
tion either. Interestingly, no differences in diagnostic 
accuracy were found for the size of the biopsy needles. 
The multifactorial regression model was used to 
evaluate the predictive factors mentioned above. Only 
the visibility of the lesion in both diagnostic methods 
(p = 0.04) and combined BIRADS-5 (p = 0.02) were 
independent predictors in this model. 
Discussion 
Atypical ductal hyperplasia is a benign prolifera-
tive breast disease, but due to the risk of coexisting 
cancer it is classified as a lesion of uncertain malig-
nant potential. In women diagnosed with ADH, the 
risk of breast cancer is 3–5-times higher than in the 
general population [19, 20]. A positive family history 
in association with ADH diagnosis has been shown 
to increase this risk even 10 times above baseline 
[21]. Therefore, women diagnosed with ADH are sub-
jected to follow-up. The diagnosis of ADH is mainly 
the consequence of breast cancer screening, and in 
the minority of patients it results from diagnostic 
procedures for breast-related symptoms or a  lump. 
Table II. Morphology of ADH in imaging examinations (MMG, USG) in the study group (N = 72)
Type of examination Morphology of lesion N %
USG Solid lump 43 59.7
No lesion 23 31.9
MMG Mass 32 44.4
Mass and cluster/area of microcalcifications 31 43.1
Cluster/area of microcalcifications 22 30.1
Architectural distortion 4 5.6
No lesion 18 25
Lesions visible in both USG and MMG 31 43.1
ADH – atypical ductal hyperplasia, MMG – mammography, USG – ultrasonography.
Table III. Clinical and pathological features of breast lesions in the patients diagnosed with invasive carci-
noma
No. MMG USG Max. size
[mm]
BIRADS Core needle biopsy
1 Microcalcifications + tumour Tumour 40 5 Marked atypia
2 Tumour Tumour 26 5 Marked atypia
3 Tumour Tumour 12 4a Moderate atypia
4 Microcalcifications + tumour Tumour 15 5 Marked atypia
5 Microcalcifications + tumour Tumour 40 5 Marked atypia
6 Microcalcifications + tumour Tumour 13 5 Moderate atypia
7 No changes Tumour 11 4b Moderate atypia
8 Tumour Tumour 35 5 Marked atypia
9 Tumour Tumour 8 4c Marked atypia
10 Microcalcifications + tumour Tumour 7 4c Marked atypia 
Coexisting intraductal papilloma 
11 Tumour Tumour 5 4a Marked atypia
MMG – mammography, USG – ultrasonography.
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In our series of patients (data not shown), 34.7% of 
patients were symptomatic, whereas 20.8% had pal-
pable lesions. A focal finding in one of the imaging 
studies is an indication for biopsy.
Atypical ductal hyperplasia is most commonly di-
agnosed based on biopsy results of microcalcifications 
detected in the screening mammography. Atypical 
ductal hyperplasia does not have typical morpholog-
ical features in ultrasonography and it is detected in 
US-guided biopsy in about 1% of cases [22]. In breast 
MR, which should be used as a diagnostic adjunct to 
US and MMG in women with greater lifetime risk of 
developing breast carcinoma [23], it can manifest as 
a small segmental or ductal focal enhancement [24].
Atypical ductal hyperplasia is found in 3–10% 
of the CNB performed for microcalcifications [7, 13, 
25]. In the analysed group of patients, ADH was di-
agnosed in 3.1% of all stereotactic procedures, and 
in 6.6% of biopsies performed for microcalcifica-
tions, which is in line with the findings reported in 
the literature. The incidence of ADH in US-guided 
biopsies was 1.6%.
For years, open surgical biopsy has been the best 
option of further treatment for ADH. It is however 
an invasive procedure associated with excision of 
breast tissue and it may cause breast deformation 
and scarring. About 70% of women will probably not 
benefit from surgical excision, as it does not reduce 
the risk of cancer in the same or contralateral breast 
[18, 26]. Moreover, the finding of ADH may affect the 
risk of breast cancer development to a lesser degree 
than previously reported [27].
Minimally invasive techniques, including the 
vacuum-assisted core needle biopsy, are an inter-
esting diagnostic and therapeutic alternative. The 
VABB turned out to be a  low-invasive technique, 
well tolerated by patients, effective, and with a low 
rate of complications. Due to the possibility of ob-
taining larger tissue sections, the risk of compli-
cations in the case of VABB is slightly higher than 
in the case of core biopsy, mainly the risk of hae-
matoma [28]. However, among 3804 patients who 
underwent VABB, only 3 patients required surgical 
treatment of haematoma. Among other complica-
tions were fat necrosis and Mondor’s disease [29]. 
Therefore, the advantage of acquiring larger sam-
ples significantly outweighs the risks associated 
with VABB.
Diagnostic accuracy of VABB ranges between 
98% and 100% for solid lesions [30]. At the same 
time, it is less invasive and cost-effective compared 
to surgical excision. 
The usefulness of minimally invasive biopsy tech-
niques in diagnosis and treatment of ADH has been 
a subject of analyses for a long time, but the main 
problem is the relatively high risk of breast cancer 
Table IV. Factors affecting underestimation of diagnosis of breast cancer
Analysed parameter Odds ratio 95% confidence interval Z statistic P-value
Age > 60 years 2.8718 0.9207–8.9575 1.818 0.0691
Menopause 1.4 0.4826–4.0611 0.619 0.5358
Clinical symptoms (nipple discharge, pain, itching) 2.9071 1.0129–8.3437 1.984 0.0473
Needle size 10 (11) G vs. 7 G 1.2500 0.4113–3.7985 0.394 0.6939
Lesion visible in USG 0.9459 0.3059–2.9253 0.096 0.9231
Lesion visible in MMG and USG 4.3750 1.4812–12.9227 2.671 0.0076
Lesion visible in MMG (including microcalcifications) 10.9091 1.3508–88.1023 2.242 0.0250
Coexisting intraductal papilloma or fibroadenoma 0.2303 0.0478–1.1096 1.830 0.0672
Coexisting intraductal papilloma 0.1818 0.0219–1.5092 1.579 0.1144
Family history of breast cancer 0.7468 0.2696–2.0681 0.562 0.5742
History of breast cancer 8.3333 0.8137–85.3463 1.786  0.0741
Lesion size over 1 cm 3.4125 1.0081–11.5515 1.973 0.0485
BIRADS 5 15.62 1.6976–143.8144 2.427 0.0152
MMG – mammography, USG – ultrasonography.
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underestimation. The simple strategy of its manage-
ment consists of reduction of indications for unnec-
essary surgery without compromising early diagno-
sis of malignancy. Rates of false-negative diagnoses 
of breast carcinoma in cases yielding ADH in CNB 
reported in the literature reach 9–54% [5–11, 13]. 
The difference between core needle biopsy and vac-
uum-assisted biopsy is related to the volume of the 
biopsy specimens and to the biopsy needle diameter 
[31]. For VABB performed with 11-7G size needles, 
the underestimation risk seems slightly lower than 
for CNB and is 9–36% [8–11, 13].
The results obtained from our group of patients 
are consistent with the findings of other authors. 
A  comparison of histopathological results of VABB 
and surgical excision demonstrated 29.2% under-
estimation, almost equally divided between DCIS 
and invasive ductal carcinoma. What is interesting, 
the use of 7 G needles did not provide better results 
than for 10 G or 11 G needles. Similar observations 
were reported by Eby et al., with respect to the nee-
dle diameters of 9 G and 11 G [32].
The suggested inferiority of CNB due to the vol-
ume of obtained biopsy caused by the smaller diam-
eter of the needle plays a role only in the comparison 
of CNB and VABB, while the size of the biopsy needle 
in VABB does not affect the underestimation risk. 
In the recent years, there have been a number of 
interesting studies suggesting that in the selected 
groups of patients with the ADH diagnosed after 
a VABB, the avoidance of surgical excision is justi-
fied [8, 14–18].
Forgeard et al. identified three subsets of pa-
tients [14]. The first consisted of those with ADH 
in microcalcifications on an area of less than 6 mm 
in diameter, showing complete removal in post-bi-
opsy mammograms. In this group of patients, no 
case of underestimation was reported. The second 
group, with low risk of coexisting malignancy (be-
low 4%), included cases with fewer than 2 foci of 
ADH in microcalcifications on an area of 6–21 mm 
or diameter of less than 6 mm, but showing incom-
plete macroscopic removal. The third group, with the 
risk of breast cancer underestimation between 36% 
and 38%, consisted of women with a diagnosis of 
more than two foci of atypical hyperplasia, the re-
moval of which was not radical, and cases of ADH 
in microcalcifications on an area with a diameter of 
more than 21 mm. For the first two groups, Forgeard 
suggested a follow-up program without surgical ex-
cision. In group 3, an open surgical biopsy remained 
a standard [14].
A  similar subset of patients was analysed by 
Caplain et al. [17] In 124 patients with diagnosed 
ADH, the underestimation of breast cancer of 28% 
was reported. Women with microcalcifications be-
low 6 mm showing complete removal in radiologi-
cal examination were followed up. While alternative 
treatment might be applied in the case of lesions on 
an area of 6–21 mm, or with at least 2 foci of ADH, 
for the lesions above 21 mm, surgery should be an 
absolute recommendation.
Nguyen et al. pointed to the role of clinical and 
pathological correlation, and included in the fol-
low-up only patients with ADH diagnosed based on 
biopsies of isolated and completely removed (> 95%) 
microcalcifications without features of marked atyp-
ia and/or necrosis in histology [15]. All cases of solid 
lesions coexisting with microcalcifications were in 
their opinion at high risk of underestimation, and 
surgical excision was mandatory. Their observations 
are similar to our findings. In our study, the presence 
of the lesion in both US and MMG was an indepen-
dent predictive factor for malignancy. 
The other independent predictor of malignancy 
in our study was the classification as BIRADS 5 in 
either US or MMG. This is in concordance with some 
authors [33], but others did not confirm this finding 
[34]. In our study, the combined BIRADS has been 
used e.g. for the higher score of US and MMG, which 
is different from the score used by others. Therefore, 
our findings are not fully comparable with the cited 
studies. 
As shown in our study, the size of the findings 
significantly affected the final histopathological re-
sult, and a diameter greater than 1 cm in a univar-
iate analysis was associated with higher risk of un-
derestimation. Similar results were reported by Chae 
et al. [20]. In other studies, which identified differ-
ent subsets of lesions (size < 6 mm, 6–21 mm and 
> 21 mm or size < 7 mm and > 7 mm), the risk of 
ADH upgrade was substantially higher for findings 
above 6–7 mm [14, 17, 35].
The risk of false-negative diagnoses was related 
to the age of the patients. However, we did not ob-
serve such a  phenomenon. This is contrary to the 
studies by Winchester et al. and Andrales et al., who 
reported a correlation of age and cancer underesti-
mation in women diagnosed with ADH in biopsy [9, 
13]. No correlation with patients’ age was found in 
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studies of Deshaies et al., Sohn et al. or Graesslin 
et al. [6, 31, 36] which suggests that age cannot de-
fine a subset of patients who do not require surgical 
excision.
Andrales et al., as well as other authors, report-
ed that the risk of underestimation correlated with 
history of previous or synchronous breast carcino-
ma [9]. However, due to different sizes of analysed 
groups, it is difficult to obtain conclusive results.
What is interesting in our study is the relative-
ly high percentage of ADH diagnoses in US-guided 
biopsies (1.6%). It should be emphasised that the 
highest risk of underestimation was found for le-
sions visible in both MMG and US, which was an 
independent predictive factor (p = 0.038). These 
results indicate that the clinical picture, radiological 
findings and pathological results should be com-
pletely consistent (‘the rule of triple assessment’). If 
histopathologically confirmed ADH is visible in both 
imaging examinations, it is always necessary to in-
sist on surgical excision.
Atypical ductal hyperplasia is a  rare diagnosis 
in CNB or VABB; therefore the majority of studies 
are based on groups including 50–150 patients. 
Some of these studies present a model of prediction 
which can indicate the group of patients in whom 
the follow-up without surgical excision is safe [37, 
38]. However, one should consider the differenc-
es between groups of patients and, what is more 
important, quite high inter-observer variability in 
pathologic diagnosis of ADH. Current guidelines can-
not precisely identify such factors that justify only 
observation of ADH patients [39]. Our study also has 
such limitations. Even the studies based on some 
additional molecular parameters did not reduce the 
underestimation rate significantly [40].
Conclusions
The vacuum-assisted core needle biopsy is one of 
the minimally invasive techniques used in diagnos-
ing ADH. As the risk of breast malignancy underesti-
mation is relatively high (29.2%), open surgical biop-
sy remains the recommended procedure, especially 
in patients with lesions detected both in mammog-
raphy and US examination. As we could not identify 
the factors that preclude cancer underestimation, all 
the women who have the diagnosis of ADH in VABB 
should be informed about the risk of cancer under-
estimation.
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